Clinical Trial Update: The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial called ExTINGUISH is evaluating Inebilizumab for Anti-NMDA receptor encephalitis and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anti-nmda Receptor Encephalitis

Drugs mentioned

• Uplizna (inebilizumab)

Snippet

Sponsor: University of Utah | Conditions: Autoimmune Encephalitis, Encephalitis | Phase 2 | Status: RECRUITING